← Back to Search

Cognitive Reappraisal for Suicide Prevention (CRISP Trial)

N/A

Recruiting

Led By Dimitris Kiosses, PhD

Research Sponsored by Weill Medical College of Cornell University

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

50 years and older

Diagnosis of any DSM-5 depression or anxiety diagnosis based on SCID-5 Clinical Trials Version

Must not have

Current Diagnosis of Bipolar I or Bipolar II with current episode hypomanic, manic or mixed

Diagnosis of Dementia

Timeline

Screening 3 weeks

Treatment Varies

Follow Up baseline, 6, 12, and 24 weeks

Awards & highlights

No Placebo-Only Group

Summary

This trial is testing a new intervention to reduce suicide risk for adults aged 50-90 who have been hospitalized for suicidal thoughts or attempts.

Who is the study for?

This trial is for adults aged 50-90 who have recently been hospitalized for suicidal thoughts or attempts. Participants must have a diagnosis of depression or anxiety, be on psychotropics, and receiving community psychotherapy. Excluded are those with psychotic disorders, bipolar I/II in manic states, dementia, severe medical issues, or language/sensory barriers.

What is being tested?

The study tests a new emotion-regulation intervention aimed at reducing suicide risk against supportive therapy. It targets middle-aged and older adults post-suicide-related hospitalization to see if the novel approach can better prevent future crises.

What are the potential side effects?

While specific side effects aren't listed for this psychological intervention trial, participants may experience emotional discomfort or distress during therapy sessions as they work through difficult feelings and experiences.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am 50 years old or older.

Select...

I have been diagnosed with depression or anxiety.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:

Select...

I have been diagnosed with Bipolar I or II and am currently experiencing a hypomanic, manic, or mixed episode.

Select...

I have been diagnosed with dementia.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ baseline, 6, 12, and 24 weeks

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~baseline, 6, 12, and 24 weeks

This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline, 6, 12, and 24 weeks for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Emotion Regulation, as measured by the Electroencephalogram (EEG), Autobiographical Affective Regulation Task (AART), and a standard picture-based emotion regulation task.

Other study objectives

Change in Suicide Severity, as measured by the Columbia Suicide Severity Rating Scale (CSSR-S)

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups

Experimental Treatment

Active Control

Group I: CRISPExperimental Treatment1 Intervention

Cognitive Reappraisal Intervention for Suicide Prevention (CRISP) is a psychosocial intervention aimed to reduce suicide risk in middle-aged and older adults who have been hospitalized for suicidal ideation or suicide attempt. CRISP offers a combination of emotion regulation techniques, including changing the subject's perspective or the way he/she thinks to improve emotion reactions. Additional strategies taught include the provision of environmental adaptation tools (notes, checklists, calendars, etc), phone calls, and a tablet application called WellPATH.

Group II: Supportive Therapy (ST)Active Control1 Intervention

Supportive Therapy focuses on: 1. facilitating expression of affect; 2. conveying to the patient that he or she is understood; 3. offering empathy; and 4. highlighting positive experiences. The ST manual aims to standardize nonspecific therapeutic factors.

0 / 4Eligibility criteria met